Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

31 Oct 2014 17:17

RNS Number : 9032V
Vernalis PLC
31 October 2014
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Vernalis plc

 

 

2 Reason for the notification (please tick the appropriate box or boxes):

 

An acquisition or disposal of voting rights

 

 

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

 

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

X

 

An event changing the breakdown of voting rights

 

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation:

 

SFM UK Management LLP

4. Full name of shareholder(s) (if different from 3.):

 

Quantum Partners LP

5. Date of the transaction and date on which the threshold is crossed or reached:

 

30 October, 2014

6. Date on which issuer notified:

 

31 October, 2014

7. Threshold(s) that is/are crossed or reached:

 

Crossed below 3%

 

8. Notified details:

A: Voting rights attached to shares

 

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Indirect

Direct

Indirect

Ordinary 1p Shares

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 GB00B3Y5L754

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Expirationdate

Exercise/ConversionPeriod

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

 

% of votingrights

 N/A

N/A

N/A

N/A

 N/A

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

 

Type of financialinstrument

Exerciseprice

Expirationdate

Exercise/Conversionperiod

Number of votingrights instrumentrefers to

% of voting rights

 

Contract for

Difference

 N/A

 N/A

 N/A

N/A

Nominal

Delta

 

Below 3%

N/A

 

Total (A+B+C)

 

Number of voting rights

Percentage of voting rights

N/A

Below 3%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

This statement relates to a Contract for Difference ("CFD") held for the account of Quantum Partners LP, a Cayman Islands exempted limited partnership ("Quantum Partners"). SFM UK Management LLP, a subadvisor to Soros Fund Management LLC, serves as investment manager to Quantum Partners and has been granted investment discretion over portfolio investments, including the CFD, held for the account of Quantum Partners.

 

 

Proxy Voting:

 

10. Name of the proxy holder:

 

N/A

11. Number of voting rights proxy holder will cease to hold:

 

N/A

12. Date on which proxy holder will cease to hold voting rights:

 

 N/A

 

13. Additional information:

 

N/A

14. Contact name:

 

Ian Garland, CEO

15. Contact telephone number:

 

0118 938 0015

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLFDMFWFFLSEFS
Date   Source Headline
8th Apr 20117:00 amRNSNotice of Results
16th Mar 20117:00 amRNSVernalis Initiates Phase I Trial of V158866
14th Mar 20117:00 amRNSAmericas Licensing Deal for tosedostat
28th Jan 20114:48 pmRNSHolding(s) in Company
21st Dec 20101:11 pmRNSHolding(s) in Company
16th Dec 20107:00 amRNSVernalis and H.Lundbeck A/S enter Collaboration
26th Nov 20104:40 pmRNSSecond Price Monitoring Extn
26th Nov 20104:35 pmRNSPrice Monitoring Extension
18th Nov 20107:00 amRNSInterim Management Statement
18th Nov 20107:00 amRNSVernalis plc: V3381 Programme Update
6th Oct 20107:00 amRNSVernalis and Servier Achieve Research Milestone
29th Jul 20107:00 amRNSInterim results for six months ended 30 June 2010
20th Jul 20104:44 pmRNSNotice of Interim Results
16th Jul 20107:00 amRNSPipeline update
29th Jun 20104:40 pmRNSSecond Price Monitoring Extn
29th Jun 20104:35 pmRNSPrice Monitoring Extension
9th Jun 20103:35 pmRNSHolding(s) in Company
7th Jun 20104:19 pmRNSHolding(s) in Company
4th Jun 20104:40 pmRNSSecond Price Monitoring Extn
4th Jun 20104:35 pmRNSPrice Monitoring Extension
3rd Jun 20103:22 pmRNSHolding(s) in Company
1st Jun 201012:32 pmRNSDirector/PDMR Shareholding
1st Jun 201012:26 pmRNSAGM Statement
19th May 20107:00 amRNSInterim Management Statement
17th May 20104:35 pmRNSPrice Monitoring Extension
4th May 20107:00 amRNSVernalis and Servier extend Oncology Collaboration
27th Apr 20105:16 pmRNSAnnual Information Update
27th Apr 20104:56 pmRNSAGM + Annual Report Notice
16th Apr 20101:17 pmRNSDirector/PDMR Shareholding
16th Apr 20101:16 pmRNSDirector/PDMR Shareholding
12th Apr 20107:00 amRNSAnnouncement of Results year ended 31 Dec 09
1st Apr 201010:30 amRNSNotice of Results
30th Mar 201012:56 pmRNSHolding(s) in Company
24th Mar 20107:00 amRNSIN-STEP Phase IIb study results
15th Mar 20107:00 amRNSVernalis earns milestone
8th Mar 20103:06 pmRNSVernalis Regains European Rights to Frovatriptan
5th Mar 20105:29 pmRNSHolding(s) in Company
5th Mar 20105:28 pmRNSHolding(s) in Company
5th Mar 20105:22 pmRNSHolding(s) in Company
2nd Mar 20105:49 pmRNSVoting Rights and Capital
1st Mar 201012:29 pmRNSResults of General Meeting
1st Mar 20107:00 amRNSPlacing & Open Offer Result
11th Feb 20104:20 pmRNSPublication of Prospectus
11th Feb 20107:00 amRNSPlacing and Open Offer
14th Dec 20097:00 amRNSVernalis announces clinical update
11th Dec 20097:00 amRNSVernalis Earns Milestone Payment
12th Nov 20097:00 amRNSInterim Management Statement
6th Oct 20094:40 pmRNSSecond Price Monitoring Extn
6th Oct 20094:35 pmRNSPrice Monitoring Extension
6th Oct 20097:00 amRNSInitiates Pilot Study of V3381 in Chronic Cough

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.